Clinical Characteristics of Rheumatoid Arthritis Patients Achieving HAQ Remission with 6 Months of Biologic Treatment

Yusuke Miwa¹, Ryo Takahashi¹, Airi Maeoka¹, Shinichiro Nishimi¹, Nao Oguro¹, Sho Ishii¹, Mika Kobuna¹, Takahiro Tokunaga¹, Masayu Umemura¹, Tsuyoshi Kasama¹, Katsunori Inagaki² and Yoichi Toyoshima³, ¹Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan, ²Department of Orthopedics, Showa University School of Med, Tokyo, Japan, ³Showa University School of Med, Shinagawa-ku Tokyo, Japan

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Biologic agents, Health Assessment Questionnaire, remission and rheumatoid arthritis (RA)

Session Information

Date: Sunday, November 8, 2015

Title: Rheumatoid Arthritis - Clinical Aspects Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Biologic agents are highly effective for rheumatoid arthritis (RA); however, not all cases achieve health assessment questionnaire (HAQ) remission. Although previous studies have reported the prognostic factors, there is no report on predictive factors for HAQ remission. To study predictive factors for HAQ remission, which is one of the treatment goals in RA, after using biologic agents for 6 months.

Methods:

The subjects were 333 RA patients treated with biologic agents for 6 months. The following patient’s characteristics were investigated: age, gender, the number of previous drugs, disease duration, the type of biologic agents, baseline steroid dosage, MTX dosage, serum RF, MMP-3, ACPA, TNF-α, and IL-6. For evaluation we used SDAI for RA disease activity, HAQ for ADL, Short Form (SF)-36 for QOL, and Hamilton Depression Rating Scale (HAM-D) or Self-rating depression scale (SDS) for depression status. HAQ remission was defined by HAQ�…0.5 after 6 months of treatment. The subjects were divided into two groups: patients with HAQ�…0.5 and patients with HAQ>0.5 at 6 months, and a retrospective study was conducted. 101 patients were excluded from the study due to loss to 6-month follow-up, and a total of 232 patients were analyzed.

Results: Compared with a group of RA patients without HAQ remission (n=68), a group of patients with HAQ remission (n=164) had younger age (54.8 ± 15.2 vs. 61.8 ± 13.3, p=0.0011), lower baseline steroid dosage (3.4 ± 3.7mg vs. 4.5 ± 3.5mg, p=0.037), lower serum MMP-3 (196 ± 234 ng/ml vs. 321 ± 551, p=0.047), lower SDAI (22.5 ± 13.4 vs. 32.1 ± 12.9, p<0.001), lower HAQ (0.39 ± 0.51 vs. 1.08 ± 0.54, p<0.001), higher SF-36 (p<0.05 in all categories), lower SDS (40.4 ± 9.9 vs. 43.5 ± 9.2, p=0.033), and lower HAM-D (5.0 ± 4.3 vs. 8.4 ± 5.0�Ap<0.001) were detected based on univariate analysis. On the other hand, only in lower HAQ score (p=0.0001) and “mental health” item of the SF-36 (p=0.0189) were detected based on logistic regression analysis.

Conclusion:

It was suggested that RA patients with lower HAQ and lower depression scores at baseline are more likely to achieve HAQ remission with biologic treatment.

Disclosure: Y. Miwa, None; R. Takahashi, None; A. Maeoka, None; S. Nishimi, None; N. Oguro, None; S. Ishii, None; M. Kobuna, None; T. Tokunaga, None; M. Umemura, None; T. Kasama, None; K. Inagaki, None; Y. Toyoshima, None.

To cite this abstract in AMA style:

Miwa Y, Takahashi R, Maeoka A, Nishimi S, Oguro N, Ishii S, Kobuna M, Tokunaga T, Umemura M, Kasama T, Inagaki K, Toyoshima Y. Clinical Characteristics of Rheumatoid Arthritis Patients Achieving HAQ Remission with 6 Months of Biologic Treatment [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/clinical-characteristics-of-rheumatoid-arthritis-patients-achieving-haq-remission-with-6-months-of-biologic-treatment/. Accessed .

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-characteristics-of-rheumatoid-arthritis-patients-achieving-haq-remission-with-6-months-of-biologic-treatment/